RBC ups Adams Respiratory to outperform

Adams Respiratory Therapeutics Inc. was upgraded to outperform from sector perform, with above average risk, by RBC Capital Markets analyst Ken Trbovich on signs that the company is in the midst of a successful launch of its new pediatric products. As a result, the analyst revised Mucinex Pediatric sales estimates to $24.5 million from $16 million in fiscal-year 2007 and to $30 million from $19 million in fiscal-year 2008. RBC also raised its 2007 earnings per share estimate to $1.75 from $1.65. Shares of the Chester, N.J.-based pharmaceutical company were up $2.14, or 5.99%, at $37.89. (Nasdaq: ARXT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.